Debevoise Advises JP Morgan as Co-Financial Advisor to Horizon Therapeutics in Its $28.5 Billion Sale to Amgen

12 December 2022

Debevoise & Plimpton LLP is advising JP Morgan as co-financial advisor to Horizon Therapeutics plc (NASDAQ: HZNP) in its $28.5 billion sale to Amgen. For more information, please see the company’s press release.

Horizon Therapeutics is a global biotechnology company headquartered in Dublin, Ireland, and is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Amgen is a highly focused biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.

The Debevoise team is led by M&A partner Andrew Bab and includes associate Colin O’Neal.